ACS Chemical Neuroscience
August 1, 2024
Samuel C Woodburn, Caleb M. Levitt, Allison M Koester et al.
28 citations
A variety of classic psychedelics and MDMA have been shown to enhance fear extinction in rodent models. This has translational significance because a standard treatment for post-traumatic stress disorder (PTSD) is prolonged exposure therapy. However, few studies have investigated psilocybin's potential effect on fear learning paradigms. More specifically, the extents to which dose, timing of...
Journal of Advances in Medicine and Medical Research
July 24, 2024
Ibrahim Lanre Folorunsho, Nkechinyere Mary Harry, Chukwubueze Obiajunwa et al.
Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition that can occur after experiencing or witnessing a traumatic event. The impact of PTSD extends beyond the individual, affecting families, communities, and society as a whole. This study aims to investigate the potential of psilocybin as a treatment for PTSD. Psilocybin, after being metabolized to psilocin, binds to...
May 23, 2024
Daniël Hoyer
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in depressed patients. Major depressive disorder comes with multiple endophenotypes; not surprisingly classical antidepressants (tricyclics, MAO inhibitors, SSRIs, SNRIs) are not universally effective. Most antidepressants target the 5-HT system,...
The British Journal of Psychiatry
May 20, 2024
David Nutt, Ilana B Crome, Allan H. Young
18 citations
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these...
Brain Sciences
March 3, 2024
Mario Renato Velit-Salazar, Eloise Cherian, Paulo R Shiroma
13 citations
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). Methods: The Preferred Reporting Items for Systematic Reviews (PRISMA) was used as a guide to structure and report the findings for this review. A...
Behavioral Neuroscience
January 18, 2024
Zahra Ghofrani-Jahromi, Sarah Nouri-Darehno, Mehrsa Rahimi-Danesh et al.
22 citations
Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on...
Current Neuropharmacology
January 5, 2024
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al.
73 citations
Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....
Journal of Indira Gandhi Institute Of Medical Sciences
2024
Rakesh Khanna
1 citation
Abstract A review of the literature on posttraumatic stress disorder (PTSD) suggests it to be a complex disorder with many contributing factors. The concept of PTSD has continued to evolve over time. A diagnosis of PTSD may be hard to get right. Studies suggest a wide variation in its presentation and diagnostic stability. It is tempting to explore the possibility of using chemicals that could...
Journal of addiction psychiatry
2024
Gianni Martire, Daniel Sipple, David Baron et al.
341 citations
Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward deficiency and stress-like anti-reward processes. And so, BPD may be reclassified as a "traumatic personality stress disorder" (TPSD) with ensuing common therapeutic strategies that may stabilize dopaminergic reward function such as...
Nature
July 13, 2023
Rich Haridy
55 citations
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.